BioCentury This WeekWUSA9
About The Show Meet The Team Program Archive Become a Sponsor
UPDATE FLASH PLAYER AND EXPERIENCE THE NEW BCTV SHOW GUIDE

Mobile Banner Image


      HOME     ABOUT BIOCENTURY     WHY BCTV?     PRESS RELEASES    FREE CONTENT    LINK TO BCTV    CONTACT US   
Advertisement



BIOCENTURY EXTRA LATEST HEADLINES


   TOP STORY

CHMP backs Zydelig, Imbruvica

EMA's CHMP issued positive opinions for several drugs on Friday, including Zydelig idelalisib from Gilead Sciences Inc. (NASDAQ:GILD) and Imbruvica ibrutinib from Pharmacyclics Inc. (NASDAQ:PCYC) and partner Johnson & Johnson (NYSE:JNJ). The committee backed approval of Zydelig in combination with rituximab to treat chronic lymphocytic leukemia (CLL) in patients who have received at least one prior therapy and as first-line therapy in patients with 17p deletion or tumor protein p53 (TP53; p53) mutation who are unsuitable for chemo immunotherapy. CHMP also backed the small molecule inhibitor of phosphoinositide 3-kinase (PI3K) delta as monotherapy to treat follicular lymphoma (FL) that is refractory to two prior lines of treatment. FL is a type of indolent non-Hodgkin's lymphoma (NHL). more >>

   FINANCIAL NEWS

Ocular, Innocoll take haircuts to get out IPO door

Ocular Therapeutix Inc. (NASDAQ:OCUL) and Innocoll GmbH (NASDAQ:INNL) priced IPOs on Friday. Ocular raised $65 million through the sale of 5 million shares at $13. The price values the company at $267.4 million. Earlier this month, the company amended the offering to sell 5 million shares at $14-$16. At the $15 midpoint, the company would have raised $75 million and been valued at $308.5 million. Morgan Stanley; Cowen; RBC Capital; and Oppenheimer are underwriters. Ocular's OTX-DP, a hydrogel-based punctum plug that delivers sustained- and tapered-release dexamethasone over one month, is in Phase III testing to treat pain and inflammation associated with cataract surgery. Data are expected in 1Q15. more >>

Applied Genetic raises $30 million in follow-on

Rare ophthalmic disease company Applied Genetic Technologies Corp. (NASDAQ:AGTC) raised $30 million through the sale of 2 million shares at $15 in a follow-on underwritten by BMO Capital Markets; Stifel; Wedbush PacGrow; Cantor Fitzgerald; and Roth Capital Partners. Applied Genetic proposed the follow-on July 11, when its share price was $19.07. more >>

   CLINICAL NEWS

Nexavar misses in Phase III breast cancer trial

Onyx Pharmaceuticals Inc. and Bayer AG (Xetra:BAYN) said Nexavar sorafenib plus capecitabine missed the primary endpoint of improving progression-free survival (PFS) vs. placebo plus capecitabine in the Phase III RESILIENCE trial to treat locally advanced or metastatic breast cancer. The double-blind, international trial enrolled 537 patients with locally advanced or metastatic HER2-negative breast cancer who are resistant to or have failed prior taxane therapy, and resistant to or failed anthracycline or for whom further anthracycline is not indicated. The partners could not be reached for next steps for Nexavar in the indication. more >>

   POLITICS & POLICY

EU data protection regulations could hinder cancer research

The draft EU General Data Protection Regulation could make cancer research "unworkable" by adding a significant administrative burden, according to a position paper published by the European Society for Medical Oncology (ESMO) on Friday. In March, the European Parliament published its position on the proposed regulation, which would set the rules under which personal data are to be handled in the EU, including for health and research use. more >>

NIH announces new Common Fund programs

NIH announced three new Common Fund programs focusing on emerging biotechnology research that could have a "transformative impact in five to 10 years." NIH told BioCentury it plans to spend $248 million on the Stimulating Peripheral Activity to Relieve Conditions (SPARC) program, which will develop high resolution neural circuit maps and neural implants that can stimulate nerves. more >>

Advertisement

SCIBX: SCIENCE-BUSINESS EXCHANGE

SCIBX: SCIENCE-BUSINESS EXCHANGE
COVER STORY

It is an RNA world

RNA-based drugs have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent, turning RNA into the biotech industry's de facto third drug modality.

TARGETS & MECHANISMS

Selecting CDK7

A Harvard Medical School team has found a cyclin dependent kinase 7 inhibitor that covalently binds a cysteine outside the enzyme's kinase domain and suppresses leukemia in mice. Syros Pharmaceuticals has licensed the compound, dubbed THZ1, for its preclinical CDK7 inhibitor program.

TRANSLATIONAL NOTES

AD mission in the U.K.

The U.K. government is responding to calls for a dementia therapy by 2025 by securing nearly L120 million (US $205 million) from U.K.-based organizations for a series of research initiatives spanning discovery to the clinic. Reaching the target might require international coordination to incentivize investors.

THERAPEUTICS

This Week in Therapeutics

Activating ADORA2B to treat obesity; stimulating IDO1 to establish endotoxin tolerance in sepsis; agonizing ATGR2 to prevent pain; and more...

TECHNIQUES

This Week in Techniques

Assessing circulating donor cell-free DNA levels to predict heart transplant rejection; modeling Ewing's sarcoma with cell-specific expression of a transgenic EWSR1-FLI1 fusion protein in mice; delivering beta-lactam antibiotics via enterobactin; and more...

User Agreement | Terms of Use | Privacy Policy | Your California Privacy Rights | Use of Images

Advertisement